GL PharmTech Overview

  • Founded
  • 2002

Founded
  • Status
  • Public

  • Employees
  • 21

Employees
  • Stock Symbol
  • 204840

Stock Symbol
  • Share Price
  • $0.58

  • (As of Friday Closing)

GL PharmTech General Information

Description

GL Pharm Tech Corp is engaged in developing and marketing pharmaceutical products. It offers products including Incrementally Modified Drugs, Generic Drug and G-SOREN Tab. It also provides generic drugs for cardiovascular, gastric, diabetes, CNS, and respiratory diseases.

Contact Information

Website
www.glpt.co.kr
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
KRX
Primary Office
  • 714, Jungang Indussia 5, 137 Sagimakgol-ro
  • Jungwon-gu
  • Seongnam-si, Gyeonggi-do
  • South Korea
+82 000-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GL PharmTech Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.58 $0.59 $0.46 - $1.15 $36.3M 62.1M 232K -$0.04

GL PharmTech Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 37,654 66,402 66,443 46,963
Revenue 11,593 10,848 10,154 9,097
EBITDA 279 (831) (623) (2,877)
Net Income (1,284) (3,254) (2,843) (4,730)
Total Assets 26,490 26,802 32,032 22,918
Total Debt 9,115 6,621 11,932 13,549
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GL PharmTech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GL PharmTech‘s full profile, request access.

Request a free trial

GL PharmTech Patents

GL PharmTech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20180256504-A1 Pregabalin-containing, high swellable, sustained-release triple layer tablet Active 01-Feb-2017 000000000 0
EP-3375438-A4 Oral sustained-release triple tablet containing pregabalin Pending 01-Feb-2017 0000000000
US-10632077-B2 Pregabalin-containing, oral sustained-release triple layer tablet Active 01-Feb-2017 0000000000 0
US-20190099376-A1 Pregabalin-containing, oral sustained-release triple layer tablet Active 01-Feb-2017 0000000000 0
EP-3375438-A1 Oral sustained-release triple tablet containing pregabalin Pending 01-Feb-2017 A61K9/2086
To view GL PharmTech’s complete patent history, request access »

GL PharmTech Executive Team (2)

Name Title Board Seat Contact Info
Brian Wang Chief Executive Officer
Park Jun Sang Director, Research & Development
To view GL PharmTech’s complete executive team members history, request access »

GL PharmTech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GL PharmTech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GL PharmTech‘s full profile, request access.

Request a free trial